139 related articles for article (PubMed ID: 23611771)
1. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
Manley PW; Blasco F; Mestan J; Aichholz R
Bioorg Med Chem; 2013 Jun; 21(11):3231-9. PubMed ID: 23611771
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P
Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813
[TBL] [Abstract][Full Text] [Related]
4. Absorption and elimination of imatinib through the rat intestine in vitro.
Kralj E; Zakelj S; Trontelj J; Roškar R; Cernelč P; Kristl A
Int J Pharm; 2014 Jan; 460(1-2):144-9. PubMed ID: 24219857
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
6. Imatinib plasma levels during successful long-term treatment of metastatic-gastrointestinal stromal tumors.
Sawaki A; Inaba K; Nomura S; Kanie H; Yamada T; Hayashi K; Okawaki M; Yamamura M; Yamaguchi Y; Hirai T; Orito E
Hepatogastroenterology; 2014 Oct; 61(135):1984-9. PubMed ID: 25713899
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs.
Ishizuka M; Nagai S; Sakamoto KQ; Fujita S
Xenobiotica; 2007 May; 37(5):503-13. PubMed ID: 17523053
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of novel adenine dinucleotide phosphate conjugates of imatinib in incubations with rat and human liver microsomes.
Ma S; Subramanian R; Xu Y; Schrag M; Shou M
Drug Metab Dispos; 2008 Dec; 36(12):2414-8. PubMed ID: 18799804
[TBL] [Abstract][Full Text] [Related]
9. Effect of St John's wort on imatinib mesylate pharmacokinetics.
Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
[TBL] [Abstract][Full Text] [Related]
10. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
11. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile.
Bleyzac N; Kebaili K; Mialou V; Bertrand Y; Goutelle S
Ther Drug Monit; 2014 Dec; 36(6):724-9. PubMed ID: 24739665
[TBL] [Abstract][Full Text] [Related]
13. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro.
Wang L; Wang Z; Xia MM; Wang YY; Wang HY; Hu GX
Can J Physiol Pharmacol; 2014 Nov; 92(11):961-4. PubMed ID: 25365188
[TBL] [Abstract][Full Text] [Related]
15. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
Bornhäuser M; Pursche S; Bonin M; Freiberg-Richter J; Jenke A; Illmer T; Ehninger G; Schleyer E
J Clin Oncol; 2005 Jun; 23(16):3855-6; author reply 3857-8. PubMed ID: 15923584
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
Russell MA; Carpenter MW; Akhtar MS; Lagattuta TF; Egorin MJ
J Perinatol; 2007 Apr; 27(4):241-3. PubMed ID: 17377606
[TBL] [Abstract][Full Text] [Related]
17. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
Rezende VM; Rivellis A; Novaes MM; de Alencar Fisher Chamone D; Bendit I
Drug Des Devel Ther; 2013; 7():699-710. PubMed ID: 23946646
[TBL] [Abstract][Full Text] [Related]
18. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
le Coutre P; Kreuzer KA; Pursche S; Bonin Mv; Leopold T; Baskaynak G; Dörken B; Ehninger G; Ottmann O; Jenke A; Bornhäuser M; Schleyer E
Cancer Chemother Pharmacol; 2004 Apr; 53(4):313-23. PubMed ID: 14658008
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
